Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups? Abstract #2049

Introduction: Neuroendocrine tumors (pNETs) are the second most common neoplasm. Most of the pNETs are diagnosed at later stages among those patients who are underprivileged. The diagnosis and treatment of neuroendocrine tumor is a continuous emotional distress for both patient and their family.
Aim(s): We aim to identify the severity of depression, emotional distress, stress and mental fatigue among those patients who are diagnosed with pancreatic neuroendocrine tumor.
Materials and methods: A cross sectional study was conducted in Shaukat Khanum Hospital, Lahore from March 2014 to April 2015. Exclusion and Inclusion criteria were made. 150 were enrolled in the study. Socio demographic characteristics were evaluated using Beck Depression Inventory and socio demographic form. Severity of depression was estimated by using Hamilton D (HAM-D). Various variables were analysed including parent’s age, level of education, socioeconomic status, gender and number of children.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr Arooj Fatima

To read results and conclusion, please login ...

Further abstracts you may be interested in

#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C
#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)
Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Eric Engelman
#829 On the Benign Side of Malignancy: How Neuroendocrine Tumors are Experienced by Patients and Their Family Carers
Introduction: Neuroendocrine tumors (NETs) are rare, slow-growing neoplasia with variable clinical presentations. Due to their non-specific symptoms and a lack of diagnostic tools, late diagnosis is common. There is little research relating to NETs as experienced by both patients and family carers.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Susanne Kall
Authors: Kall S, Spichiger E, Stoll H, ...
#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Grietje Bouma
#1387 FOLFOX in Neuroendocrine Tumors
Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Marjorie Faure
Authors: Faure M, Raoul J L, Autret A, Mineur L, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.